Curasight A/S announced that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design. The trial will investigate Curasight's theranostic (therapeutics/diagnostics) approach by testing the diagnostic platform uTRACE®? and the treatment platform uTREAT®?

in brain cancer (Glioblastoma), neuroendocrine tumors (NET), head-and-neck cancer (HNSCC), non-small cell lung cancer (NSCLC), and pancreatic cancer. To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024. The trial of five cancer types in parallel takes advantage of the theranostic platform working across tumor types as uPAR is expressed in the majority of all solid cancers.

This also increases the likelihood of entering into partnering with pharma companies. The new study is in addition to Curasight's ongoing Phase II trial investigating uTRACE in prostate cancer as part of the partnership agreement with Curium Inc., where the first interim data is expected third quarter of 2024. Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight is entitled to receive up to USD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.